Highlights

  • FY26 revenue increased 77% to A$6.30 million, reflecting expansion of consumer and clinical activities.
  • The statutory net loss narrowed to A$10.86 million, while customer cash receipts reached A$5.65 million.
  • Clinical subscription sites increased from two to 17 by 30 June 2026.
  • SphygmoCor Cloud development focuses on extending arterial health measurements through software.
  • Regulatory work and the costs of commercial expansion remain central operating considerations.

Conneqt Health Limited (ASX:CQT) develops arterial health measurement technology for consumer, clinical and research applications, including the CONNEQT Pulse device and SphygmoCor platform. Its FY26 reporting details expanding device sales, an emerging subscription business and work to deliver vascular measurements through software. These activities connect central blood pressure technology with the company’s broader commercial strategy.

How Central Aortic Pressure Measurement Fits the Platform

A conventional arm-cuff reading measures pressure in peripheral arteries. Central aortic pressure relates to pressure closer to the heart and can provide different information about arterial function. SphygmoCor technology analyses pulse waveforms to derive central cardiovascular measurements. The distinction is important: derived central measures depend on validated acquisition methods and algorithms, and are not interchangeable with a routine arm-cuff reading.

Conneqt Health Limited (ASX:CQT) is working to make its established vascular biomarker algorithms available through cloud-based systems. The company’s FY26 annual report identifies SphygmoCor Cloud, software as a medical device and biomarker services as development areas. Its June-quarter submission to the US Food and Drug Administration was a pre-submission, not an approval or marketing clearance.

FY26 Revenue, Loss and Operating Model

For the financial year ended 30 June 2026, Conneqt Health Limited (ASX:CQT) reported revenue of A$6.30 million, an increase of 77%. Revenue was approximately A$4.0 million in the second half, compared with approximately A$2.3 million in the first half. Customer cash receipts increased 65% to A$5.65 million, according to its annual report.

The statutory net loss narrowed 40% to A$10.86 million. Total expenses, including cost of goods sold, declined 22% in FY26. Cash and cash equivalents at 30 June 2026 were A$2,566,332. The reported loss indicates that increased sales had not yet translated into statutory profitability, while the cash balance highlights the importance of funding ongoing operations and product development.

Consumer Devices and Clinical Subscriptions

The CONNEQT Pulse device is central to the consumer offering. Beyond initial device revenue, Conneqt Health Limited (ASX:CQT) is developing paid digital services, including Care+ and Cardiology Reports. Management described these as ways to engage customers after the hardware purchase, although future subscription adoption remains dependent on customer demand and delivery.

The enterprise business made progress converting pilots into longer-term agreements. Initial pilots became two-year commercial arrangements in the December 2025 quarter, and clinical subscription sites increased from two to 17 by 30 June 2026. Research activities generated approximately A$2.3 million in FY26 revenue, while a separate approximately A$1.1 million US clinical trial services contract was secured.

Development, Regulation and Execution Considerations

Conneqt Health Limited (ASX:CQT) reported submitting an FDA pre-submission for SphygmoCor Cloud during the June quarter and identified a mid-FY27 clearance submission as its objective. A planned submission is not evidence of regulatory clearance. The company must also manage device manufacturing, customer acquisition expenditure, clinical deployment and software development while maintaining sufficient liquidity.

Key Insights

The FY26 figures show Conneqt Health Limited (ASX:CQT) broadening from specialised measurement equipment into connected consumer devices, clinical subscriptions and software development. Central aortic pressure analysis remains an important technical foundation, but commercial performance depends on product adoption, recurring revenue conversion, regulatory processes and expenditure control. Its next disclosures can establish how these activities develop beyond the reported FY26 period.